| Market Capitalization (Millions $) |
7,933 |
| Shares
Outstanding (Millions) |
369 |
| Employees |
2,900 |
| Revenues (TTM) (Millions $) |
1,751 |
| Net Income (TTM) (Millions $) |
-297 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
33 |
Business Description
Legend Biotech Corporation is a biotechnology company that focuses on discovering and developing innovative cell therapy treatments for patients with cancer. The company was established in 2014 as a joint venture between Genscript Biotech Corporation and Janssen Biotech, Inc., and is headquartered in Somerset, New Jersey, USA, with additional facilities in China.
The company's main focus is on the development of chimeric antigen receptor (CAR) T cell therapies, a type of immunotherapy that involves genetically modifying a patient's own immune cells to recognize and target cancer cells. Legend Biotech's lead product candidate is LCAR-B38M, a CAR T therapy that targets the B-cell maturation antigen (BCMA) and is being developed for the treatment of multiple myeloma.
LCAR-B38M has shown promising results in early-phase clinical trials, with high response rates and durable remissions in patients with relapsed/refractory multiple myeloma. The therapy has also demonstrated a favorable safety profile, with no severe toxicities observed in clinical trials.
In addition to LCAR-B38M, Legend Biotech is also developing other CAR T therapies targeting different cancer antigens, including CD20 and CD2 The company is also exploring the potential of other cell-based therapies, including TCR T cell therapies and CAR NK cell therapies.
Legend Biotech has a strong research and development team, with expertise in cell biology, immunology, and oncology. The company has collaborations with academic and industry partners, including the University of Pennsylvania, Tmunity Therapeutics, and Janssen Biotech, to advance its pipeline of cell therapies.
In 2019, Legend Biotech became a public company through an initial public offering (IPO) on the NASDAQ Global Select Market, raising $424 million in gross proceeds. The company's leadership team includes Frank Fan, CEO, Dr. Fang Zhou, President and Chief Scientific Officer, and Mr. Eric Zhang, Chief Financial Officer.
Overall, Legend Biotech is a promising biotechnology company that is focused on developing innovative cell therapies to treat cancer. With a strong pipeline of products and a talented R&D team, the company is well-positioned to make significant contributions to the field of cancer immunotherapy.
Company Address: Legend Biotech Corporation Somerset 8873 NJ
Company Phone Number: 317-5050 Stock Exchange / Ticker: NASDAQ LEGN
|
0.38% 
72.51 %